Patient Age Group

Edit Profile

News & Events

  • Breakthrough cystic fibrosis drug gives hope, transforms lives

    Praised by experts as a breakthrough for patients with a particular form of cystic fibrosis, ivacaftor was approved by the United States Food and Drug Administration (FDA) in January 2012 and is the first of its kind to treat the underlying defects of the disease, rather than manage its symptoms.

  • Research of Sam Moskowitz, MD

    The Moskowitz research program at MGHfC focuses on chronic airway infection and host-pathogen interactions in cystic fibrosis (CF), encompassing the fields of microbiology, biochemistry, immunology, epithelial biology, bacterial and eukaryotic genetics, and pulmonary medicine.

Back to Top